Atanasio Pandiella Alonso-rekin lankidetzan egindako argitalpenak (4)

2014

  1. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

    Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516

2012

  1. CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype

    Haematologica, Vol. 97, Núm. 7, pp. 1110-1114

  2. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. Deficient spindle assembly checkpoint in multiple myeloma

    PLoS ONE, Vol. 6, Núm. 11